When suboptimal post-protocol care in oncology trials is rewarded

Area of Science:

• Oncology Clinical Trials
• Regulatory Science
• Evidence-Based Medicine

Background:

• Overall survival (OS) is the primary endpoint for oncology drug approval and treatment guidelines.
• Inadequate post-protocol care for control arms can artificially inflate survival advantages.
• This issue impacts trial interpretation across various cancer types and treatment settings.

Purpose of the Study:

• To highlight how suboptimal post-protocol care can distort survival outcomes in oncology trials.
• To examine the implications of such distortions on regulatory advantages and guideline recommendations.
• To propose solutions for systematically evaluating post-protocol care in clinical trial design and review.

Main Methods:

• Analysis of three oncology trial examples (melanoma, breast, urothelial cancer) with suboptimal post-protocol care.
• Examination of how current regulatory and guideline systems may reward trials with apparent survival gains.
• Proposal for integrating post-protocol data into trial evaluation and regulatory consultations.

Main Results:

• Inadequate post-protocol care was identified as a potential contributor to apparent survival advantages in diverse oncology settings.
• The current system may inadvertently favor trials with distorted survival data.
• Apparent survival gains can lead to unwarranted regulatory advantages or stronger guideline recommendations.

Conclusions:

• Post-protocol data must be a central component in evaluating oncology trial survival outcomes.
• Systematic consideration of post-protocol care during pre-submission regulatory consultations is essential.
• Ensuring optimal post-trial care is critical for the generalizability of trial results and informed drug authorization.